NCT06476808 A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
| NCT ID | NCT06476808 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Bristol-Myers Squibb |
| Condition | High-grade Serous Ovarian Carcinoma (HGSOC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2024-09-06 |
| Primary Completion | 2028-12-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 240 participants in total. It began in 2024-09-06 with a primary completion date of 2028-12-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Eligibility Criteria
Inclusion Criteria * Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained. * Participants must have an unresectable/metastatic carcinoma. Exclusion Criteria * Participants must not have Leptomeningeal metastases. * Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment. * Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment. * Other protocol-defined Inclusion/Exclusion criteria apply.
Frequently Asked Questions
Who can join the NCT06476808 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying High-grade Serous Ovarian Carcinoma (HGSOC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06476808 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06476808 currently recruiting?
Yes, NCT06476808 is actively recruiting participants. Visit ClinicalTrials.gov or contact Bristol-Myers Squibb to inquire about joining.
Where is the NCT06476808 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States, Hackensack, United States, Columbus, United States and 1 additional location.
Who is sponsoring the NCT06476808 clinical trial?
NCT06476808 is sponsored by Bristol-Myers Squibb. The trial plans to enroll 240 participants.